- Prevalence, Incidence, and Factor Concentrate Usage Trends of Hemophiliacs in Taiwan
-
Tu TC, Liou WS, Chou TY, Lin TK, Lee CF, Chen JD, Cham TM, Chung MI
- KMID: 1776920
- Yonsei Med J.
- 2013 Jan;54(1):71-80.
- doi: 10.3349/ymj.2013.54.1.71
PURPOSE: Hemophilia A and B (HA, HB) are the most common X-linked inherited bleeding disorders. The introduction of factor concentrates has allowed for control of the lifelong chronic disease. However,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
-
Hyun SY, Park SY, Lee SY, Kook H, Paik SH, Jang IJ, Lee KS
- KMID: 2366332
- Yonsei Med J.
- 2015 Jul;56(4):935-943.
- doi: 10.3349/ymj.2015.56.4.935
PURPOSE: Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. This prospective clinical trial was conducted to evaluate the efficacy, safety, and... -
- CITED
-
- Close
- SHARE
-
- Close
